Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $679K fell 85.6% year over year. Sequentially, it rose 21.3% from the prior quarter.
Context
- Research & development increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.27M USD
- Year-over-year change
- +122.9%
- 2-year CAGR
- +50.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.27M | +122.9% |
| FY2024 | 2024-12-31 | 2.81M | +1.4% |
| FY2023 | 2023-12-31 | 2.77M | — |
Research & Development vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 research & development of $2.23M is the 7th highest of the 8 companies compared; the peer median is $82.1M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.83M | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $145.36M | +345.0% | +69.4% | 1223.2% | |
| LTM Mar 2026 | $109.15M | +200.2% | +34.1% | — | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M | -29.1% | +37.8% | — |
| LTM Mar 2026 | $23.82M | -28.9% | -5.7% | — | |
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.23M | — | — | — |
| LTM Mar 2026 | $1.22M | +34.5% | +46.4% | 4.4% | |
| Peer median (excluding PLYX) | $82.1M | -9.4% | +34.1% | 757.1% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.